South West Public Health Scientific Conference
Wednesday 5th February 2014
The Winter Gardens, Weston-super-Mare
Call For Abstracts
You are invited to submit abstracts for Oral and Poster presentation at the South West Public Health Scientific Conference to be held on Wednesday 5th February 2014.
The aim of the conference is to showcase both service and university based public health research and evaluation from across the South West.
You are invited to submit abstracts of your work from across the full range of public health and from all related disciplines. Abstracts should clearly include your research question, methodology and results. To help with the submission of abstracts, guidance and an example abstract are attached.
Abstracts should be sent to the conference organisers via Beth.Carpenter@southwest.hee.nhs.uk and be received by 18.00 hours on Wednesday 30th October 2013.
If you would like to discuss the content of your abstract please contact one of the following members of the conference abstract committee:
Prof Yoav Ben-Shlomo Tel: 0117 928 7206 Professor in Clinical Epidemiology Email: Y.Ben-Shlomo@bristol.ac.uk
Dr Paul Pilkington Tel: 0117 328 8860 Senior Lecturer in Public Health Email: Paul.Pilkington@uwe.ac.uk
Guidance For Abstracts
Please complete the attached submission form and return it to Beth.Carpenter@southwest.hee.nhs.uk with a copy of your abstract, quoting Scientific Conference Abstract in the email subject line.
All abstracts must be received by 18.00 hours on Wednesday 30th October 2013. Abstracts received after this time will not be considered.
Important information regarding abstract layout:
- The abstract must be no longer than 300 words maximum (excluding title, authors and affiliations, keywords and references)
- Text should be single line spaced with justified margins
- Each abstract must use Word Arial font in size 11 point
- Abstracts should be saved as a Word document using the author’s name as the file name
- Abstracts should be presented in accordance with the following guidance:
- The title of the abstract must be in bold. The first letter of each word of the title must be in upper sentence case.
- Full details of all the authors must be provided. This should include name; role and organisation/affiliation
- The name of the author that wishes to present at the conference must be underlined
- The authors’ roles and organisations/affiliations should be written in italics
- The aim of the abstract presentation must be clear
- It is advised to use the following sub-headings where relevant and appropriate:
- Results / Findings
- Conclusions / Recommendations
Abstracts that fail to adhere to the required abstract layout as outlined above will be rejected. Abstracts will be reproduced on the conference website exactly as submitted, so please check abstracts carefully before submission.
Abstracts will be peer reviewed and presenting authors of successful abstracts will be notified by 18th November 2013.
Please note that acceptance of your abstract does not give you a delegate place at the conference and you will be required to register a place when registration opens in late November.
For those submitting multiple abstracts, please be aware that if more than one abstract is accepted for oral presentation, each must be presented by a different individual at the conference.
Oral presentations will generally be allocated 12 minutes, followed by 3 minutes for discussion.
Poster presentations will be provided with space for one board.
Smoking Cessation Treatment and the Risk of Depression, Suicide and Self-harm in the Clinical Practice Research Datalink: a Cohort Study
Thomas K; Martin R; Davies N; Windmeijer F; Metcalfe C; Gunnell D
Department of Social Medicine, University of Bristol, Bristol
Aim: To compare the risk of suicide, self-harm and depression in patients prescribed varenicline and bupropion with those prescribed nicotine replacement therapy (NRT).
Background: Smoking is a major cause of premature mortality and preventable morbidity in the UK. Varenicline is recommended by NICE as an option for smokers who want to quit smoking. However there are safety warnings that smoking cessation medicines, such as varenicline and bupropion, may increase the risk of fatal and non-fatal self-harm.
Methodology: We followed up 203 413 adult patients with a first prescription of a smoking cessation product between September 1st 2006 and 31st December 2010 in the UK’s Clinical Practice Research Datalink (CPRD). NRT was the most commonly prescribed (70% of prescriptions), followed by varenicline (24.9%) and bupropion (5.2%). Approximately half of general practices in the CPRD were linked to National Mortality data and Hospital Episode Statistics. Our primary outcomes were suicide and hospital admission for self-harm; depression was a secondary outcome. Cox regression methods were used.
Results: We detected 2008 primary care records of depression, 53 hospital admissions for self-harm and 6 confirmed suicides. We found no evidence that patients prescribed varenicline had higher risks of suicide, self-harm or depression compared with those prescribed NRT; hazard ratios (HRs) 0.90 (95% confidence interval 0.10, 8.30), 0.88 (0.43, 1.80) and 0.73 (0.65, 0.82) respectively. There were no suicides in patients prescribed bupropion. We found no evidence that patients prescribed bupropion had higher risks of self-harm, HR 1.03 (0.32, 3.37) or depression, HR 0.88 (0.71, 1.08) compared with patients prescribed NRT. Updated results will be available at the conference.
Conclusions: There is no evidence of an increased risk of suicidal behaviour in patients prescribed varenicline or bupropion compared to those prescribed NRT. These findings are reassuring for users and prescribers of smoking cessation medicines.
Please return to Beth.Carpenter@southwest.hee.nhs.uk by 18.00 hours on Wednesday 30th October 2013 quoting Scientific Conference Abstract in the email subject line